CAI · Healthcare
Caris Life Sciences Inc
49/100
Smart-money confidence2 of 3 sources positive
Moderate — mixed signals
company insiders are buying
Hedge funds
52
Congress
No data
Insiders
100
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Consensus buy — 2 of 3 sources positive →
Market cap
$6.5B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About CARIS LIFE SCIENCES INC
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome…
Who's behind the signal
Every informed buyer we can see on CAI, across all three feeds.
Hedge funds · 9
Duquesne Family Office (Druckenmiller)
New position
D.E. Shaw & Co
New position
AQR Capital Management
New position
Gotham Asset Mgmt (Greenblatt)
Increased +1008%
Coatue Management
Unchanged
Point72 (Steve Cohen)
Decreased −51%
+3 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
Company insiders
Buying
Recent buys2
Not a model pick — but on our radar.
CARIS LIFE SCIENCES INC isn't in the top-10 model right now, but 9 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
9
Investors
3
New positions
1
Increasing
4
Decreasing
1
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.6×
% of portfolio
1.1%
Position change
NEW
1.1% of Duquesne Family Office's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of AQR Capital Management's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+1008%
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.4×
% of portfolio
0.6%
Position change
—
0.6% of Coatue Management's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−51%
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−58%
0.0% of Millennium Management's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
−45%
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−98%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to CARIS LIFE SCIENCES INC
No insider trades found in the last 90 days
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell CARIS LIFE SCIENCES INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订